Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

2024). Although the accumulation of GA during the development of tea shoots and the regulation of plant hormones on GA biosynthesis in tea plants have been preliminarily confirmed, the regulation ...

The trial indicated good tolerability of APG990 in healthy participants, and the company plans to initiate a Phase 1b head-to-head study against DUPIXENT later this year, with results expected in ...

DUPIXENT supported by positive APG990 interim Phase 1 results ... are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating ...

Dupixent has emerged as a major growth driver for Regeneron ... targeting a large market opportunity in anticoagulation with a differentiated mechanism of action. Conservative estimates suggest a $3 ...

Pharmacy Benefit Managers (PBMs) have evolved from relatively obscure cost-saving entities into powerful industry players with significant influence over drug pricing and access. Their business ...

Reminds me of a 1980s music video by Herbie Hancock(?) featuring a twitching humanoid mechanism. Can't recall the title but it was in heavy play on MTV back in ancient times. Smokey_Bear February ...

pre-clinical testing showed a 'Dupixent-like mechanism of action through the targeting of the IL-4/IL-13 pathway'. A Phase 1b trial for atopic dermatitis or AD is expected to kick off this quarter ...